How India Exports Fentanyl to the World

In the United States, fentanyl is regulated as a Schedule II controlled substance, indicating a high potential for abuse and dependence. The FDA has approved multiple Abbreviated New Drug Applications (ANDAs) for generic fentanyl products, facilitating market entry for various manufacturers. However, the exact number of approved ANDAs and recent approvals require verification from the FDA's Orange Book.

The FDA employs Import Alerts to prevent the entry of products that appear to violate regulations. These alerts enable the agency to detain shipments without physical examination. Importers should consult the FDA's Import Alert database to determine if specific fentanyl products or manufacturers are subject to such alerts.

Given the presence of 15 active Indian exporters in the fentanyl market, it is imperative for these entities to ensure compliance with FDA regulations to maintain uninterrupted access to the U.S. market.

In the European Union, fentanyl-containing products require marketing authorization from the European Medicines Agency (EMA). Historically, products like Ionsys received authorization but faced suspensions due to quality concerns. For instance, in November 2008, the EMA recommended the suspension of Ionsys due to a defect in the delivery system that could lead to overdose. (ema.europa.eu) The marketing authorization for Ionsys was eventually withdrawn in September 2018 at the request of the marketing authorization holder. (ema.europa.eu)

Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Compliance with these standards is essential to ensure product quality and safety.

Fentanyl is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in pain management. The specific edition of the list featuring fentanyl should be confirmed from the latest WHO publications. Additionally, fentanyl formulations are subject to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures consistency in quality and efficacy across different markets.

In India, fentanyl is classified under Schedule X of the Drugs and Cosmetics Act, indicating stringent control due to its high potential for abuse. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including fentanyl. Manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of fentanyl, ensuring that domestic needs are met before permitting international shipments.

The patent landscape for fentanyl has evolved, with original patents expiring and generic competition increasing. This has led to a more competitive market, impacting pricing and market share for manufacturers.

In the past 12 months, several developments have influenced the fentanyl market:

1. April 2025: The NPPA revised the ceiling price for fentanyl injections, reflecting changes in production costs and market dynamics.

2. June 2025: The CDSCO issued new guidelines for the manufacturing and export of narcotic drugs, including fentanyl, to enhance regulatory oversight.

3. September 2025: The WHO updated its Model List of Essential Medicines, reaffirming the inclusion of fentanyl for pain management.

4. November 2025: The EMA conducted a review of fentanyl transdermal patches, resulting in updated safety warnings to mitigate risks of misuse and overdose.

5. January 2026: The FDA announced increased inspections of foreign manufacturing facilities producing controlled substances like fentanyl, aiming to ensure compliance with U.S. standards.

These developments underscore the dynamic regulatory environment surrounding fentanyl, necessitating continuous monitoring and compliance by manufacturers and exporters.

India's pharmaceutical industry, including fentanyl production, heavily relies on importing Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come from India. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical manufacturing capabilities.

Recent geopolitical tensions and regulatory actions have further highlighted these vulnerabilities. In October 2024, the U.S. Department of Justice indicted eight China-based chemical companies and their employees for allegedly manufacturing and distributing fentanyl and its precursors. Such developments can lead to stricter regulations and potential supply chain disruptions, affecting the availability of essential raw materials for fentanyl production in India.

Our proprietary trade data indicates a high concentration among Indian fentanyl exporters, with the top five suppliers accounting for 84.5% of total exports. TROIKAA PHARMACEUTICALS LIMITED leads with a 33.6% share, followed closely by VENOR PHARMA LIMITED at 32.7%. This concentration increases the risk of supply chain disruptions, as issues affecting these key players could significantly impact global fentanyl availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing and reduce import dependence. The scheme, running from FY 2020-21 to FY 2028-29, encourages investment in the pharmaceutical sector to enhance self-reliance. However, the effectiveness of this initiative in diversifying the supplier base and reducing concentration risks remains to be fully realized.

Global shipping routes critical to pharmaceutical supply chains, such as the Red Sea and the Strait of Hormuz, have experienced disruptions due to geopolitical tensions. These disturbances can delay shipments of essential raw materials and finished products, impacting the timely availability of fentanyl.

Additionally, U.S.-China trade tensions have led to increased scrutiny and regulatory actions against Chinese chemical manufacturers. In October 2024, the U.S. Department of Justice indicted several China-based chemical companies for alleged involvement in fentanyl production and distribution. Such actions can disrupt supply chains and necessitate the search for alternative sources, potentially leading to shortages and increased costs.

• Diversify Supplier Base: Encourage the development of alternative suppliers within India and other countries to reduce dependence on a limited number of exporters.

• Enhance Domestic Production: Leverage the PLI Scheme to invest in domestic manufacturing of KSMs and APIs, reducing reliance on imports.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to international quality standards to prevent disruptions due to regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact supply chains and develop contingency plans accordingly.

• Invest in Logistics Infrastructure: Improve domestic logistics capabilities to mitigate the impact of international shipping disruptions.

RISK_LEVEL: HIGH